Abpro Corporation (ABP) 10-Year Financial Performance & Capital Metrics

ABP • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutAbpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic partnership with Abpro Bio Co. Ltd and NJCTTQ. The company was formerly known as Abpro Corporation and changed its name to Abpro Holdings, Inc. in November 2024. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.Show more

Revenue $183K +50.0%
EBITDA -$9M +15.1%
Net Income -$7M +38.2%
EPS (Diluted) -23.10 +38.4%
Gross Margin 100%
EBITDA Margin -5081.42% +43.4%
Operating Margin -5421.31% +43.7%
Net Margin -3951.91% +58.8%
ROE -
ROIC -
Debt/Equity -
Interest Coverage -25.64 +95.0%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Weak momentum: RS Rating 9 (bottom 9%)
✗Sales declining 35.9% over 5 years
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-35.85%

3Y-27.49%

TTM50%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM15.82%

EPS CAGR

10Y-

5Y-

3Y-

TTM58.67%

ROCE

10Y Avg-238.31%

5Y Avg-348.64%

3Y Avg-757.38%

Latest-

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.33B	9.92	70.86	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	720.1M	4.25	11.18	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	881.27M	2.22	-1.73	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	572.64M	7.30	-2.38			-117.82%	0.18
NKTRNektar Therapeutics	719.28M	35.36	-4.07	9.22%	-192.87%	-141.9%	1.69
IMNMImmunome, Inc.	2.52B	22.85	-4.57	-35.5%	-23.01%	-84.4%	0.03
IBRXImmunityBio, Inc.	3.89B	3.95	-6.37	22.71%	-422.28%
NRIXNurix Therapeutics, Inc.	1.91B	18.86	-6.55	-29.15%	-292.5%	-65.76%	0.05

Profit & Loss

	Dec 2016	Dec 2017	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.69M	2.2M	480K	2.03M	122K	183K
Revenue Growth %	-	0.31%	-0.78%	3.23%	-0.94%	0.5%
Cost of Goods Sold+	1.71M	1.52M	8.63M	9.75M	0	0
COGS % of Revenue	1.02%	0.69%	17.97%	4.81%	-	-
Gross Profit+	-28K	676K	-8.15M	-7.72M	122K	183K
Gross Margin %	-0.02%	0.31%	-16.97%	-3.81%	1%	1%
Gross Profit Growth %	-	25.14%	-13.05%	0.05%	1.02%	0.5%
Operating Expenses+	5.35M	13.03M	6.83M	8.96M	11.87M	10.1M
OpEx % of Revenue	3.17%	5.92%	14.23%	4.42%	97.28%	55.21%
Selling, General & Admin	4.22M	6.93M	6.83M	8.96M	7.6M	7.12M
SG&A % of Revenue	2.5%	3.15%	14.23%	4.42%	62.31%	38.91%
Research & Development	1.13M	6.1M	8.63M	9.75M	4.27M	2.98M
R&D % of Revenue	0.67%	2.77%	17.97%	4.81%	34.97%	16.3%
Other Operating Expenses	0	31K	-8.63M	-9.75M	0	0
Operating Income+	5.38M	-12.36M	-14.98M	-16.68M	-11.75M	-9.92M
Operating Margin %	3.19%	-5.61%	-31.2%	-8.22%	-96.28%	-54.21%
Operating Income Growth %	-	-3.3%	-0.21%	-0.11%	0.3%	0.16%
EBITDA+	5.44M	-12.2M	-14.45M	-15.83M	-10.95M	-9.3M
EBITDA Margin %	3.23%	-5.54%	-30.11%	-7.8%	-89.79%	-50.81%
EBITDA Growth %	-	-3.24%	-0.18%	-0.1%	0.31%	0.15%
D&A (Non-Cash Add-back)	64K	156K	523K	856K	792K	622K
EBIT	-6.04M	-12.36M	-14.98M	-16.64M	-11.68M	-6.84M
Net Interest Income+	0	0	-17K	-200K	40K	-378K
Interest Income	0	0	0	48K	63K	9K
Interest Expense	69K	0	17K	248K	23K	387K
Other Income/Expense	-11.48M	31K	242K	-200K	40K	2.69M
Pretax Income+	-6.11M	-12.33M	-14.73M	-16.89M	-11.71M	-7.23M
Pretax Margin %	-3.63%	-5.6%	-30.7%	-8.32%	-95.95%	-39.52%
Income Tax+	-595K	31K	0	330K	0	0
Effective Tax Rate %	0.9%	1%	1%	1.02%	1%	1%
Net Income+	-5.51M	-12.36M	-14.73M	-17.21M	-11.71M	-7.23M
Net Margin %	-3.27%	-5.61%	-30.7%	-8.48%	-95.95%	-39.52%
Net Income Growth %	-	-1.24%	-0.19%	-0.17%	0.32%	0.38%
Net Income (Continuing)	-5.51M	-12.36M	-14.73M	-17.21M	-11.71M	-7.23M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	0	0	549K	549K	549K	549K
EPS (Diluted)+	-14.10	-31.50	-47.70	-55.50	-37.50	-23.10
EPS Growth %	-	-1.23%	-0.51%	-0.16%	0.32%	0.38%
EPS (Basic)	-14.10	-31.50	-47.70	-55.50	-37.50	-23.10
Diluted Shares Outstanding	387.93K	392.2K	309.13K	310.4K	311.9K	313.27K
Basic Shares Outstanding	387.93K	392.2K	309.13K	310.4K	311.9K	313.27K
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	7.25M	14.96M	6.86M	9.65M	1.9M	3.78M
Cash & Short-Term Investments	7.08M	14.52M	6.56M	7.33M	723K	2.85M
Cash Only	7.08M	14.52M	6.56M	7.33M	723K	2.85M
Short-Term Investments	0	0	0	0	0	0
Accounts Receivable	108K	184K	40K	2.03M	88K	323K
Days Sales Outstanding	23.39	30.51	30.42	365.18	263.28	644.24
Inventory	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-
Other Current Assets	0	0	0	292K	1.09M	603K
Total Non-Current Assets+	434K	2.18M	1.03M	2.21M	1.46M	885K
Property, Plant & Equipment	114K	1.46M	695K	1.8M	1.07M	455K
Fixed Asset Turnover	14.78x	1.51x	0.69x	1.13x	0.11x	0.40x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	131K	196K	186K	364K
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	320K	716K	207K	207K	204K	66K
Total Assets+	7.69M	17.14M	7.89M	11.85M	3.35M	4.66M
Asset Turnover	0.22x	0.13x	0.06x	0.17x	0.04x	0.04x
Asset Growth %	-	1.23%	-0.54%	0.5%	-0.72%	0.39%
Total Current Liabilities+	1.89M	2.62M	4.47M	10.87M	12.44M	19.61M
Accounts Payable	76K	534K	1.91M	8.15M	7.92M	3.94M
Days Payables Outstanding	16.19	127.81	80.73	305.05	-	-
Short-Term Debt	0	0	0	0	1.74M	2.87M
Deferred Revenue (Current)	128K	99K	0	64K	0	0
Other Current Liabilities	1.69M	1.99M	0	0	0	80K
Current Ratio	3.84x	5.71x	1.53x	0.89x	0.15x	0.19x
Quick Ratio	3.84x	5.71x	1.53x	0.89x	0.15x	0.19x
Cash Conversion Cycle	-	-	-	-	-	-
Total Non-Current Liabilities+	18.14M	36.99M	351K	76.72M	76.05M	0
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	0	351K	1.12M	455K	0
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	0	36.69M	0	75.6M	75.6M	0
Total Liabilities	20.03M	39.61M	4.82M	87.59M	88.49M	19.61M
Total Debt+	0	0	558K	1.87M	2.89M	3.33M
Net Debt	-7.08M	-14.52M	-6M	-5.45M	2.17M	478K
Debt / Equity	-	-	0.18x	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-1.30x	-	-	-	-	-
Interest Coverage	77.91x	-	-881.00x	-67.28x	-510.70x	-25.64x
Total Equity+	-12.35M	-22.46M	3.07M	-75.73M	-85.14M	-14.95M
Equity Growth %	-	-0.82%	1.14%	-25.66%	-0.12%	0.82%
Book Value per Share	-31.82	-57.28	9.93	-243.99	-272.96	-47.71
Total Shareholders' Equity	-12.35M	-22.46M	2.52M	-76.28M	-85.68M	-15.49M
Common Stock	12K	14K	9K	9K	9K	5K
Retained Earnings	-16.62M	-28.95M	-76.65M	-93.86M	-105.57M	-116.1M
Treasury Stock	0	0	-33K	-33K	-33K	0
Accumulated OCI	0	0	0	0	0	0
Minority Interest	0	0	549K	549K	549K	549K

Cash Flow

	Dec 2016	Dec 2017	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.88M	-9.47M	-10.95M	-8.95M	-7.4M	-9.03M
Operating CF Margin %	-2.9%	-4.3%	-22.82%	-4.41%	-60.67%	-49.34%
Operating CF Growth %	-	-0.94%	-0.16%	0.18%	0.17%	-0.22%
Net Income	-6.11M	-12.33M	-14.73M	-17.21M	-11.71M	-7.23M
Depreciation & Amortization	64K	156K	523K	856K	792K	622K
Stock-Based Compensation	1.17M	1.32M	2.17M	4.02M	2.31M	1.93M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	725K	1.02M	301K	0	0	-3.03M
Working Capital Changes	-733K	363K	793K	3.39M	1.21M	-1.32M
Change in Receivables	20K	-76K	40K	-1.99M	1.94M	-235K
Change in Inventory	-515K	-44K	0	0	0	0
Change in Payables	-268K	257K	0	6.24M	-743K	-860K
Cash from Investing+	-108K	-752K	-87K	-65K	-48K	0
Capital Expenditures	-108K	-762K	-12K	-65K	-48K	0
CapEx % of Revenue	0.06%	0.35%	0.03%	0.03%	0.39%	-
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	10K	-75K	0	0	0
Cash from Financing+	11.93M	17.67M	-180K	9.78M	849K	11.16M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	11.93M	17.67M	0	0	-371K	-2.09M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-4.99M	-10.23M	-10.96M	-9.02M	-7.45M	-9.03M
FCF Margin %	-2.96%	-4.65%	-22.84%	-4.44%	-61.07%	-49.34%
FCF Growth %	-	-1.05%	-0.07%	0.18%	0.17%	-0.21%
FCF per Share	-12.86	-26.10	-35.47	-29.05	-23.89	-28.83
FCF Conversion (FCF/Net Income)	0.89x	0.77x	0.74x	0.52x	0.63x	1.25x
Interest Paid	0	0	30K	30K	16K	1K
Taxes Paid	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-479.81%	-	-	-
Gross Margin	-1.66%	30.71%	-1697.29%	-380.73%	100%	100%
Net Margin	-327.24%	-561.43%	-3069.79%	-848.45%	-9595.08%	-3951.91%
Debt / Equity	-	-	0.18x	-	-	-
Interest Coverage	77.91x	-	-881.00x	-67.28x	-510.70x	-25.64x
FCF Conversion	0.89x	0.77x	0.74x	0.52x	0.63x	1.25x
Revenue Growth	-	30.62%	-78.19%	322.71%	-93.99%	50%

Frequently Asked Questions

Growth & Financials

Abpro Corporation (ABP) reported $0.2M in revenue for fiscal year 2024. This represents a 89% decrease from $1.7M in 2016.

Abpro Corporation (ABP) grew revenue by 50.0% over the past year. This is strong growth.

Abpro Corporation (ABP) reported a net loss of $14.0M for fiscal year 2024.

Dividend & Returns

Abpro Corporation (ABP) had negative free cash flow of $13.6M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener